Skip to main content

Table 3 Association between CKD (eGFR < 60 ml/min/1.73m2) and CSVD

From: Chronic kidney disease and its association with cerebral small vessel disease in the general older hypertensive population

 

Odds ratio

CI

p-value

Association between CKD and CSVD, not adjusted for covariates

WMHs1

1.67

1.03–2.71

0.039

Lacunar infarcts2

1.49

0.68–3.27

0.321

CMBs3

1.72

1.04–2.82

0.033

Cortical atrophy 4

1.62

1.01–2.59

0.045

Composite CSVD 5

1.8

1.12–2.89

0.016

Modified STRIVE 6

1.67

0.89–3.14

0.11

Association between CKD and CSVD, adjusted for age and sex

WMHs1

1.44

0.88–2.37

0.152

Lacunar infarcts2

1.57

0.70–3.53

0.273

CMBs3

1.61

0.96–2.70

0.074

Cortical atrophy 4

1.52

0.93–2.48

0.093

Composite CSVD 5

1.55

0.95–2.53

0.079

Modified STRIVE 6

1.38

0.71–2.66

0.344

  1. eGFR calculated from creatinine and cystatin C in non-underweight participants and on cystatin C in underweight participants (BMI < 23) using the CKD-EPI formula
  2. eGFR ≥ 60 ml/min/1.73m2 as reference
  3. Binary logistic regression models were used to examine the association between CKD (eGFR < 60 ml/min/1.73m2) and WMHs, lacunar infarcts, CMBs, cortical atrophy, CSVD composite, and modified STRIVE.
  4. Covariates: Age, sex
  5. Abbreviation BMI = Body mass index, CKD = Chronic kidney disease, CKD-EPI = chronic kidney disease epidemiology collaboration, CMBs = Cerebral microbleeds, CSVD = Cerebral small vessel disease, eGFR = estimated glomerular filtration rate, GCA = Global cortical atrophy, MRI = Magnetic resonance imaging, SD = Standard deviation, STRIVE = Standards for reporting vascular changes on neuroimaging, WMHs = White matter hyperintensities
  6. 1 WMHs defined as Fazekas scale ≥ 2
  7. 2 Lacunar infarcts defined as presence of ≥ 1 lacunar infarct
  8. 3 CMBs defined as presence of ≥ 1 CMB
  9. 4Cortical atrophy defined as GCA ≥ 1 and/or Koedam score ≥ 1 and/or ≥ 1 frontal/frontotemporal/temporal atrophy
  10. 5 Presence of CSVD according to the composite CSVD variable was defined as Fazekas scale ≥ 2 and/or presence of ≥ 1 lacunar infarct and/or ≥ 1 CMB
  11. 6Presence of CSVD according to the modified STRIVE variable was defined as Fazekas scale ≥ 2 and/or presence of ≥ 1 lacunar infarct and/or presence of ≥ 1 CMB and/or presence of cortical atrophy and/or presence of central atrophy
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us